All News
Are T cells the missing link in pre-clinical RA?
T cells are known to play a key role in RA pathogenesis and the diversity of the T cell repertoire is known to be reduced in RA.
Read Article
Targeted therapies in Sjogren’s syndrome: are we close?
There is a clear unmet need for new and effective therapies in primary Sjogren’s Syndrome (pSS) patients, as there are no current licensed therapies.
EULAR 2023 – Day 3 Report
https://t.co/qseMZiaHFq https://t.co/pnijisF9Jt
Links:
Dr. John Cush RheumNow ( View Tweet)
Unmasking Lupus Pregnancy: Adherence and Drug Monitoring Dilemmas
Preliminary data from a lupus pregnancy LEGACY cohort presented at #EULAR23 are alarming.
Dr. Bella Mehta ( @bella_mehta ) shares more.
https://t.co/cY2G4s4yR0 https://t.co/isepEb8OXD
Links:
Dr. John Cush RheumNow ( View Tweet)
RA and cancer risk in the biologic era
RA is known to be historically associated with site specific cancers, especially lung skin and lymphomas. This risk was described as likely to be supported by chronic systemic inflammation before the biologic era.
https://t.co/4Pe6SIS6yb https://t.co/e2enjkXoly
Links:
Dr. John Cush RheumNow ( View Tweet)
AI in RA: the story grows along the patient pathway
The use of AI to analyse large data sets using its subset component machine learning (ML) has taken centre stage recently in the management of rheumatic conditions including RA.
https://t.co/Jv4dmV2tlU https://t.co/KkgW0cD1QM
Links:
Dr. John Cush RheumNow ( View Tweet)
#EULAR23 – Day 2 Report
Day 2 at the international EULAR Congress meeting is always bigger and busier. There are more sessions to choose from and more audience questions in the big auditorium presentations.
https://t.co/vjrG7ez2fX https://t.co/HUuDImzqZA
Links:
Dr. John Cush RheumNow ( View Tweet)
EULAR points to consider in the match from PSO to PSA. 5 overarching principles and 10 points to consider. The presence of synovitis in PSO could be used as an outcome for prevention trials, Zabotti A et al, Abst#OP0062 #EULAR2023 @RheumNow https://t.co/tbnuhBCjTU
Dr. Antoni Chan synovialjoints ( View Tweet)
The definition of early axSpA based on expert consensus after going through the Delphi process by ASAS is that the duration of axial symptoms is equal or less than 2 years. Navarro-Compan V, Abst#OP0055 #EULAR2023 @RheumNow https://t.co/5byn0kBEIQ
Dr. Antoni Chan synovialjoints ( View Tweet)
Dual IL-17A/F inhibition with Bimekizumab reduced MRI inflammatory change in the SIJ and spine in AxSpA, and increasing proportion achieving MRI remission at Wk52, Abst#POS0246 #EULAR2023 @RheumNow https://t.co/w4VkkUklGl
Dr. Antoni Chan synovialjoints ( View Tweet)
The International Map of AxSpA (IMAS) of >5k patients: delay mean 7.4+/-9 years, 75% active disease, 60% poor mental health, 21% sick leave, 4.6 GP visits before diagnosis, fear=disease progression, hope=relief of pain, IMAS Abst#POS0298 #EULAR2023 @RheumNow https://t.co/wB9Jtbgvy7
Dr. Antoni Chan synovialjoints ( View Tweet)
Important from @cappelliMD @jhrheumatology irAE cohort on predictors of DMARD requirement in ICI-inflammatory arthritis, and persistent ICI-IA post-ICI cessation.
The better we can predict these patients, the more we can get the right therapy early
POS0951 #EULAR2023 @RheumNow https://t.co/YGTRl71505
David Liew drdavidliew ( View Tweet)
EULAR 2023 recommendations on the management of fatigue in IRMDs. 4 overarching principles and 4 recommendations for monitoring and assessment of fatigue, Dures E Abst#P0370 #EULAR2023 @RheumNow https://t.co/AirPlRLNjZ
Dr. Antoni Chan synovialjoints ( View Tweet)
The course of symptoms in CSA to RA showed greater severity in the ACPA+ group compared to the ACPA- group. This correlated with MRI-subclinical joint score, suggesting different underlying processes Khidir S Abst#POS319 #EULAR2023 @RheumNow https://t.co/C2ADAkkSM2
Dr. Antoni Chan synovialjoints ( View Tweet)
Better at Predicting RA from MRI: Humans or Computers?
https://t.co/xRVatfiRKS https://t.co/Gwypq8lcdl
Links:
Dr. John Cush RheumNow ( View Tweet)
The future of lupus treatment is oral therapies?
There has been an explosion of trials in SLE, including nonrenal and glomerulonephritis studies.
@Janetbirdope
https://t.co/IQ9bxbTSV4 https://t.co/jVYOphxpAE
Links:
Dr. John Cush RheumNow ( View Tweet)
In an early SpA (DESIR) cohort, the occurrence of a first pregnancy did not seem to increase the number of imaging abnormalities of the SIJ. Overall no significant changes in radiographic and MRI imaging abnormalities of the SIJ, Molto A, Abst#POS0303, #EULAR2023 @RheumNow
Dr. Antoni Chan synovialjoints ( View Tweet)
Supervised 12 weeks High-intensity interval training program
Improves Vo2 peak in IA patients
But does not improve pain or fatigue
It is disappointing but it is also a small study w/ n=30 pts in each group.
It is unclear if the type of exercise has an impact on outcome https://t.co/Plk7sflrh5
Aurelie Najm AurelieRheumo ( View Tweet)
What happens when an AI-based symptom checker & an online self-referral tool play Rheumatologists?
They don't seem to do great yet!
600 new pts, outw/ 36% dvlpd IA
IA Sens 62% Spe 47%
Tool Sens 66% Spe 54%
More work needed to implement these in practice
#EULAR23 @Rheumnow
Aurelie Najm AurelieRheumo ( View Tweet)
RheumNow’s expanded coverage of the #EULAR2023 meeting is sponsored in part by Bristol Myers Squibb. All content is chosen by RheumNow and its faculty.
Dr. John Cush RheumNow ( View Tweet)